{"entity":{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","aka":[],"tldr":"Nykode makes cancer vaccines that teach the immune system to attack tumours. One is built from each patient's own tumour mutations; another targets cancers caused by the HPV16 virus, such as cervical cancer.","summary":"Nykode Therapeutics (Euronext Oslo: NYKD) develops immunotherapies on its Vaccibody platform, a DNA-encoded molecule that delivers antigens to antigen-presenting cells to induce strong and durable T cell responses. VB10.16 (abi-suva) is an off-the-shelf vaccine against HPV16 E6 and E7. In the phase 2 VB-C-02 trial in advanced cervical cancer with atezolizumab, median progression-free survival was 6.3 months and median overall survival was not reached beyond 25 months in PD-L1 positive patients (April 2023). A collaboration with MSD tests VB10.16 with pembrolizumab in HPV16-positive head and neck cancer. VB10.NEO is a fully individualised neoantigen vaccine with optimised manufacturing reported in 2026. In August 2026 Nykode raised about NOK 286 million in a private placement to fund VB10.NEO partnering, the move of abi-suva from phase 2 to phase 3 and a tolerance platform, with shareholders Rasmussengruppen and Andenæsgruppen participating.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.nykode.com"},{"label":"Private placement completed (August 2026)","url":"https://nykode.com/wp-content/uploads/2026/09/260827-Private-Placement-Completed.pdf"},{"label":"Phase 2 VB10.16 final results in cervical cancer","url":"https://www.globenewswire.com/news-release/2023/04/18/2649342/0/en/nykode-therapeutics-announces-positive-final-results-from-its-phase-2-trial-of-vb10-16-in-combination-with-pd-l1-inhibitor-atezolizumab-in-advanced-cervical-cancer.html"},{"label":"MSD clinical collaboration in HPV16-positive head and neck cancer","url":"https://www.globenewswire.com/news-release/2022/12/06/2568545/0/en/nykode-therapeutics-announces-clinical-collaboration-with-msd-to-evaluate-vb10-16-in-combination-with-keytruda-pembrolizumab-in-patients-with-hpv16-positive-head-and-neck-cancer.html"}],"tags":[],"related":[],"cancers":["cervical","head-and-neck"],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine","shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced."],"hq":"Oslo","country":"NO","companyType":"biotech","website":"https://www.nykode.com","ticker":"NYKD.OL","stage":"public","investors":[],"funding":[{"round":"Crossover","year":2026,"source":"https://nykode.com/wp-content/uploads/2026/09/260827-Private-Placement-Completed.pdf","note":"Public follow-on private placement on Euronext Oslo: NOK 286 million gross, 65 million new shares at NOK 4.40"}]},"route":"/companies/nykode-therapeutics/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}]}}